A repeated injection of polyethyleneglycol-conjugated recombinant human butyrylcholinesterase elicits immune response in mice

Toxicology and Applied Pharmacology

Volumn 231, Issue 3, 2008, Pages 423-429

  Chilukuri, Nageswararao ^a   Sun, Wei ^a   Parikh, Kalpana ^a   Naik, Ramachandra S ^a   Tang, Lin ^a   Doctor, Bhupendra P ^a   Saxena, Ashima ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Bioscavengers; Circulatory stability; Immunogenicity; Organophosphorus compounds; PEG conjugation; Recombinant human butyrylcholinesterase

Indexed keywords

CHOLINESTERASE; MACROGOL; MONOMER; ORGANOPHOSPHORUS COMPOUND; RECOMBINANT ANTIBODY; RECOMBINANT HUMAN BUTYRYLCHOLINESTERASE; RECOMBINANT HUMAN BUTYRYLCHOLINESTERASE ANTIBODY; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONJUGATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; ENZYME MECHANISM; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NEUROPROTECTION; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES; BUTYRYLCHOLINESTERASE; HUMANS; MALE; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

MUS;

EID: 50849122970     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.05.016     Document Type: Article

References (41)

1. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., and Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252 (1977) 3582-3586
2. Altamirano C.V., and Lockridge O. Conserved aromatic residues of the C-terminus of butyrylcholinesterase mediate the association of tetramers. Biochemistry 38 (1999) 13414-13422
3. Ashani Y., Shapira S., Levy D., Wolfe A.D., Doctor B.P., and Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem. Pharmacol. 41 (1991) 37-41
4. Ashani Y., and Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphate toxicity. Toxicol. Sci. 77 (2004) 358-367
5. Ashwell G., and Morell A.G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. 41 (1974) 99-128
6. Ashwell G., and Harford J. Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 51 (1982) 531-554
7. Chilukuri, N., Parikh, K., Sun, W., Naik, R.S., Tipparaju, P., Doctor, B.P., Saxena, A., 2005. Polyethylene glycosylation prolongs the circulatory stability of recombinant human butyrylcholinesterase. Chem. Biol. Interact. 157-158, 115-121.
8. Chilukuri, N., Sun, W., Naik, R.S., Parikh, K., Tang, L., Doctor, B.P., Saxena, A., in press. Effect of polyethyleneglycol modification on the circulatory stability and immunogenicity of recombinant human butyrylcholinesterase. Chem. Biol. Interact.
9. Day J.F., Thornburg R.W., Thorpe S.R., and Baynes J.W. Carbohydrate-mediated clearance of antibody and antigen complexes from the circulation. J. Biol. Chem. 255 (1980) 2360-2365
10. Doctor, B.P., Saxena, A. 2005. Bioscavengers for the protection of humans against organophosphate toxicity. Chem. Biol. Interact. 157-158, 167-171.
11. Doctor B.P., Toker L., Roth E., and Silman I. Microtiter assay for acetylcholinesterase. Anal. Biochem. 166 (1987) 399-403
12. Duysen E.G., Bartles C.F., and Lockridge O. Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J. Pharmacol. Exp. Ther. 302 (2002) 751-758
13. Ellman G.L., Courtney A.D., Andres Jr. V., and Featherstone R.M. A new and rapid colorimetric determination of acetycholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
14. Hershfield M.S. PEG-ADA: an alternative to haplo identical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum. Mutat. 5 (1995) 107-112
15. Hinds K.D., and Kim S.W. Effects of PEG conjugation on insulin properties. Adv. Drugs. Deliv. Res. 54 (2002) 505-530
16. Huang Y.J., Huang Y., Baldassarre H., Wang B., Lazaris A., Leduc M., Bilodeau A.S., Bellemare A., Cote M., Herskovits P., Touati M., Turocotte C., Valeanu L., Lemee N., Wilgus H., Begin I., Bhatia B., Rao K., Neveu N., Brochu E., Pierson J., Hockley D.K., Cerasoli D.M., Lenz D.E., Karatzas C.N., and Langerman S. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl. Acad. Sci. (USA) 104 (2007) 13603-13608
17. Inada Y., Furukawa M., Sasaki H., Kodera Y., Hiroto M., Nishimura H., and Matsushima A. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends. Biotechnol. 13 (1995) 86-91
18. Jenkins T., Balinisky D., and Patient D.W. Cholinesterase in plasma: first reported absence in the Bantu: half-life determination. Science 156 (1967) 1748-1749
19. Katre N.V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144 (1990) 209-213
20. Kronman C., Chitlaru T., Elhanany E., Velan B., and Shafferman A. Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins. J. Biol. Chem. 275 (2000) 29488-29502
21. Kronman C., Cohen O., Raveh L., Mazor O., Ordentlich A., and Shafferman A. Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication. Toxicology 233 (2007) 40-46
22. Laub P.B., and Gallo J.M. NCOM-a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J. Pharm. Sci. 85 (1996) 393-395
23. Lehrman M.A., Pizzo S.V., Imber M.J., and Hill R.L. Binding of fucose-containing glycoproteins by hepatic lectins. J. Biol. Chem. 261 (1986) 7412-7418
24. Lenz, D.E., Maxwell, D.M., Koplowitz, I., Clark, C.R., Capacio, B.R., Cerasoli, D.M., Federko, J.M., Luo, C., Saxena, A., Doctor, B.P., Olsonm, C., 2005. Protection against soman poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem. BioI. Interact. 157-158, 205-210.
25. Lockridge O., Eckerson H.W., and La Du B.N. Interchain disulfide bonds and subunit organization in human serum cholinesterase. J. Biol. Chem. 254 (1979) 8324-8330
26. Ostergaard D., Viby-Mogensen J., Hanel H.K., and Skovgaard L.T. Half-life of plasma cholinesterase. Acta Anaesthesiol. Scand. 32 (1988) 266-269
27. Parekh R.B., Dwek R.A., Rudd P.M., Thomas J.R., and Rademacher T.W. N-glycosylation and in vitro enzymatic activity of human recombinant tissue plasminogen activator expressed in Chinese hamster ovary cells and a murine cell line. Biochemistry 28 (1989) 7670-7679
28. Pepinsky B.R., LePage J.D., Gill A., Chakraborty A., Vaidyanathan S., Green M., Baker D.P., Whalley E., Hochman P.S., and Martin P. Improved pharmacokinetic properties of a polyethylene glycol modified form of interferon-b-1a with preserved in vitro bioavailability. Exp. Ther. 297 (2001) 1059-1066
29. PJB Publications Ltd., 1998. Amgen halts growth factor trials. Scrip 92 (1998) 568a
30. Rademacher T.W., Parekh R.B., and Dwek R.A. Glycobiology. Annu. Rev. Biochem. 57 (1988) 785-838
31. Raveh L., Grunwald J., Marcus D., Papier Y., Cohen E., and Ashani Y. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. Biochem, Pharmacol, 45 (1993) 2465-2474
32. Raveh L., Grauer E., Grunwald J., Cohen E., and Ashani Y. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol. Appl. Pharmacol. 145 (1997) 43-53
33. Rosenberg Y., Luo C., Ashani Y., Docto r.B.P., Fischer R., Wolfe G., and Saxena A. Pharmacokinetic and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase. Life Sci 72 (2002) 125-134
34. Sasaki H., Bothner B., Dell A., and Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem. 262 (1987) 12059-12076
35. Saxena A., Raveh L., Ashani Y., and Doctor B.P. Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Biochemistry 36 (1997) 7481-7489
36. Saxena A., Ashani Y., Raveh L., Stevenson D., Patel T., and Doctor B.P. Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol. Pharmacol. 53 (1998) 112-122
37. Saxena A., Luo C., Chilukuri N., Maxwell D.M., and Doctor B.P. Novel approaches to medical protection against chemical warfare nerve agents. In: Romano Jr. J.A., Lukey B.J., and Salem H. (Eds). Chemical Warfare Agents. Chemistry, Pharmacology, Toxicology, and Therapeutics. Second Edition (2007) 145-174
38. Sun W., Naik R.S., Luo C., Doctor B.P., and Saxena A. Pharmacokinetics and immunologic consequences of repeated administrations of purified butyrylcholinesterases in mice. Proceedings of The Joint Service Scientific Conference on Chem. & Biol. Defense Res. (2004) 17-20 Nov 2004
39. Takeuchi M., Inoue N., Strickland T.W., Kubota M., Wada M., Shimizu R., Hoshi S., Kozutsumi H., Takasaki S., and Kobata A. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. (USA) 86 (1989) 7819-7822
40. Yang Z., Wang J., Lu Q., Xu J., Kobayashi Y., Takakura T., Takimoto A., Yoshioka T., Lian C., Chen C., Zhang D., Zhang Y., Li S., Sun X., Tan Y., Yagi S., Frenkel E.P., and Hoffman R.M. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methionase in primates. Canc. Res. 64 (2004) 6673-6678
41. Zhou Q., Kyaziki J., Echelard Y., Meade H.M., Higgins E., Cale E.S., and Edmunds T. Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of trans-genic goats. J. Biotechnol. 117 (2005) 57-72